Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
neurodegenerative diseases
Fierce Biotech
Amylyx discontinues rare neuro program after missing ph. 2 mark
The phase 2 portion of the trial found no difference in patients receiving AMX0035 compared to placebo at 24 weeks.
Gabrielle Masson
Aug 27, 2025 10:40am
Congress's biotech report, NIH ban, GSK-ABL—Fierce Pharma Asia
Apr 11, 2025 10:31am
Neurotech nabs first nod for eye disease cell therapy implant
Mar 10, 2025 9:50am
Zevra lines up $150M from sale of PRV tied to Miplyffa approval
Feb 27, 2025 9:58am
IntraBio snags FDA nod in rare disease just days after Zevra
Sep 25, 2024 9:50am
Zevra snags FDA approval for new lysosomal storage disorder med
Sep 20, 2024 1:54pm
